FDA Approves fitusiran for Hemophilia A and B Dr. Kamal Kant Kohli2 April 2025 9:15 AM ISTThe FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or B, with or without...
Fitusiran Antithrombin-Based Regimen Ensures Effective Bleed Control in Hemophilia: ATLAS-OLE Study Medha Baranwal1 April 2025 8:45 AM ISTUSA: A recent analysis from the ATLAS-OLE study has provided promising insights into the long-term safety and efficacy of fitusiran, an...
USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors Ruchika Sharma29 March 2025 11:30 AM ISTParis: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia...
CDSCO Panel Approves Sanofi's Protocol Amendment proposal for Fitusiran study Dr. Divya Colin7 Sept 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO panel Approves Sanofi's Protocol Amendment Proposal for to study Fitusiran Dr. Divya Colin2 Jun 2024 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved drug major...
Monthly fitusiran injections effective for bleeding reduction in patients with haemophilia A and B, study shows Dr. Kamal Kant Kohli6 April 2023 8:00 PM ISTUSA: Monthly prophylactic injections of fitusiran have shown promise in reducing bleeds in patients with haemophillia A or B, according to randomised...
Prophylaxis fitusiran may improve QoL and decrease bleeding in hemophilia patients: ATLAS-INH trial MD Editorial Team20 Dec 2021 9:00 AM ISTDelhi: The effectiveness of fitusiran 80 mg monthly subcutaneous prophylaxis in persons with hemophilia A or B with inhibitors was proven in Phase 3...
